Cambridge, UK - Cambridge Antibody Technology  (LSE: CAT; NASDAQ: CATG) today
announces that preliminary results of a Phase I clinical trial of CAT-354, a
human anti-IL13 monoclonal antibody being studied as a potential treatment for
severe asthma, showed CAT-354 to be well tolerated with no safety concerns
identified.

The objective of the trial, which commenced in September 2004, was to assess the
safety, tolerability and pharmacokinetics of CAT-354. It was a double-blind,
placebo-controlled, rising single dose intravenous study in 34 mild asthmatic
patients. Preliminary results showed that CAT-354 was well tolerated at all
doses and there were no identified safety concerns; pharmacokinetics were as
anticipated. The trial results will be submitted to an appropriate scientific
meeting in due course.

Based on these results, CAT is planning to start a clinical pharmacology study
in the fourth quarter of 2005. This is being planned as a repeat dose allergen
challenge study in patients with asthma.

Patrick Round, VP Development at CAT, commented: 'CAT-354 is an important
product candidate for CAT and this trial was the first clinical step in its
development as a potential treatment for severe asthma. We are encouraged by
these preliminary results and are now moving forward with plans for a second
clinical trial.'...